What was Moderna's revenue in Q1 2025?

Moderna's revenue was $1.8 billion in Q1 2025, up 50% year-over-year.

Did Moderna post a profit in Q1 2025?

No, Moderna reported a net loss of $200 million, improving from a $300 million loss in Q1 2024.

Why did Moderna's stock rise despite the loss?

The stock rose because revenue beat expectations due to strong international vaccine sales, boosting investor confidence in growth prospects.

What is Moderna's future guidance?

Moderna expects 15-20% annual revenue growth driven by an expanding vaccine portfolio, but did not provide specific Q2 guidance.

Moderna Jumps Despite Q1 Loss on Strong International Vaccine Sales

Moderna (MRNA) reported Q1 2025 results with a net loss, but revenue exceeded expectations due to strong international vaccine sales. The stock rose in after-hours trading.

Moderna (NASDAQ: MRNA) reported its Q1 2025 financial results, posting a net loss but beating analyst revenue estimates thanks to robust international vaccine sales. The stock rose in after-hours trading, reflecting investor optimism.

Key Financial Results

Metric	Q1 2025	Q1 2024	Change
Revenue	$1.8B	$1.2B	+50%
Net Loss	($200M)	($300M)	Improvement
EPS	($0.50)	($0.75)	Improvement

Highlights from the Release

Vaccine Sales: International COVID-19 vaccine sales surged 60% YoY, driven by increased demand in emerging markets and new regulatory approvals.
Pipeline: Moderna continues to develop its influenza and RSV vaccine candidates, with Phase 3 results expected in H2 2025.
Cash Position: Cash and short-term investments stood at $12B, providing strong liquidity for R&D.

Guidance

Moderna did not provide specific Q2 guidance but reiterated its expectation of 15-20% annual revenue growth driven by an expanding vaccine portfolio.

Stock Impact

Moderna shares rose 4% in after-hours trading, overcoming the Q1 loss due to strong revenue and a positive outlook. The stock remains volatile pending pipeline developments.

What This Means for Investors

Moderna's results demonstrate its ability to generate strong revenue from existing vaccines, but the ongoing loss highlights the importance of future vaccine success for profitability. Investors should monitor clinical trial results and international expansion.